Immunic (NASDAQ:IMUX) Stock Rating Lowered by StockNews.com

Immunic (NASDAQ:IMUX) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

IMUX has been the subject of a number of other research reports. D. Boral Capital reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Immunic in a report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Immunic in a report on Friday. One analyst has rated the stock with a sell rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $12.67.

Immunic Trading Up 6.6 %

NASDAQ:IMUX opened at $1.26 on Friday. The company has a market capitalization of $113.32 million, a P/E ratio of -1.02 and a beta of 1.87. The firm has a fifty day simple moving average of $1.02 and a 200-day simple moving average of $1.26. Immunic has a 12 month low of $0.92 and a 12 month high of $2.11.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in IMUX. State Street Corp raised its holdings in Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares in the last quarter. 683 Capital Management LLC boosted its position in shares of Immunic by 2.2% during the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after purchasing an additional 15,349 shares in the last quarter. Bridgeway Capital Management LLC boosted its position in shares of Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after buying an additional 22,200 shares in the last quarter. Focus Partners Wealth boosted its position in shares of Immunic by 1.1% in the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after buying an additional 23,610 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Immunic in the 3rd quarter valued at about $50,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.